ReviewInternational journal of molecular sciences2019
Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Neoadjuvant and Adjuvant Chemotherapy for Variant Histology Bladder Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Immunohistochemistry scoring for human epidermal growth factor receptor 2 can be used to predict pathological response to cisplatin-based neoadjuvant chemotherapy in a subset of immunohistochemically subtyped muscle-invasive bladder cancer.Virchows Archiv : an international journal of pathology · 2026Article
- Treatment Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Propensity Score Overlap Weighting Analysis of a Multicenter Taiwanese Cohort.European urology open science · 2025Article
- Identification of Molecular Subgroups of Muscle-Invasive Urothelial Bladder Cancer and Their Impact on Treatment Outcome.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Review
- Review
- The Prevalence of p16 Expression in Urothelial Bladder Cancer in a Tertiary Care Hospital of Chattogram, Bangladesh.Iranian journal of pathology · 2023Article
- Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.Frontiers in oncology · 2023Article
- Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.Cancers · 2022Review
- The effect of neoadjuvant chemotherapy among patients undergoing radical cystectomy for variant histology bladder cancer: A systematic review.Arab journal of urology · 2022Review
- Ferroptosis-Related Long Noncoding RNAs Have Excellent Predictive Ability for Multiomic Characteristics of Bladder Cancer.Oxidative medicine and cellular longevity · 2022Article
- Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture.Cell reports. Medicine · 2021Article
- Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma.World journal of urology · 2021Article
- Diagnostic ureteroscopy for upper tract urothelial carcinoma: friend or foe?Arab journal of urology · 2021Review
- Advances in bladder cancer biology and therapy.Nature reviews. Cancer · 2021Review
- CDKN1A/p21American journal of cancer research · 2021Article
- Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.Urologic oncology · 2020Article
- Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").Translational andrology and urology · 2019Article
- Special Issue on Molecular Research Efforts in Urothelial Carcinoma: Summary of Included Topics.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinoma of the bladder (UCB) and upper tracts (UTUC) is often regarded as one entity and is managed generally with similar principles. While neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is an established standard of care in UCB, strong evidence for a similar approach is lacking in UTUC. The longest survival is seen in patients with complete response (pT0) on pathological examination of the RC specimen, but impact of delayed RC in nonresponders may be detrimental. The rate of pT0 following NAC in UTUC is considerably lower than that in UCB due to differences in access and instrumentation. Molecular markers have been evaluated to try to predict response to chemotherapy to reduce unnecessary treatment and expedite different treatment for nonresponders. A variety of potential biomarkers have been evaluated to predict response to cisplatin based chemotherapy including DNA repair genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.